In patients with ascites, how do you decide when carvedilol/NSBBs are still within a safe-and-effective “window”, and which specific thresholds make you hold or discontinue therapy?

I would direct readers to our accompanying editorial that was published along with this paper. Some methodological concerns with this trial including lacking of etiology of liver disease and an open-label design. We know that patients with alcohol associated liver disease can have recompensation wit...